Friday, February 01, 2019 9:08:18 PM
Msg 15583 of 31285 at 6/27/2016 10:10:44 PM by
libertyhound
The following message was updated on 6/27/2016 10:12:45 PM.
In response to msg 15580 by Rob Cos view thread
Re: JMP last night- development- stage names that we believe offer compelling value for the biotech investor. Also rare opportunity to acquire large caps at < 1 x's growth....
"Alzheimers is one of the most intractable diseases known to medicine, and chipping away at this devastating illness could go a long way toward reinstituting confidence amongst investors (and hopefully, the generalist) that no problem is too large for current medical science to resolve or beat back. Further, the general consensus is that a successful Alzheimer’s disease drug could become the largest selling drug on the planet, outstripping sales of Ibrance (Pfizer, PFE, NC) and immune checkpoint inhibitors like Opdivo (Bristol-Myers Squibb, BMY, NC)."
*Considering the 'very' preliminary early indications of astounding efficacy, it is possible that AVXL (MC of ~ $250M), currently trialing their A2-73 in Australia, may be long-shot favorite to watch for Alzheimer's - they don't really appear to be pursuing the 'chipping away' (read incremental improvements) approach though.....seem more aligned with going for the Holy Grail approach; their approach is NOT a variation of the popular plaque reduction route.
From a 5/10/16 SA piece by Lane Simonian
"Moreover, science seems to back the early results. Alzheimer's is most likely a disease caused by oxidative stress which can probably be treated with certain antioxidants. Anavex 2-73 partially fits this bill as by impeding the interaction between PSD 95 and neuronal nitric oxide synthase, it reduces the formation of peroxynitrite (ONOO-). Peroxynitrite inhibits the uptake of choline, the enzyme choline acetyltransferase, and the release of acetylcholine through muscarinic acetylcholine receptors which prevents the retrieval of short-term memories and it activates caspase 3 causing the death of neurons. (Image one, Image two, and Study.)
If Anavex 2-73 reduces the formation of peroxynitrite sufficiently it would prevent the further decline in acetylcholine and the death of neurons. In short it would stop the progression of Alzheimer's disease. If it partially reverses the damage done by peroxynitrite, it would increase acetylcholine levels (and thus the retrieval of short-term memory) and the regeneration of neurons in the hippocampus. In short, it would partially reverse Alzheimer's disease. The early data suggests the latter is what is happening with Anavex 2-73."
*No idea whether his (Lane Simonian) interpretation of the 'apparent' mechanism of action is fully correct, but the very preliminary 'results' appear to indicate a trend for unheard of efficacy - their trial is for early Alzheimer's btw, and further 12 week and possibly 26 week results are expected at the upcoming late July AAIC Alzheimer's Conference.
BTW - A2-73 was recently awarded ODD for Infantile Spasms and Rett Syndrome, ODD to their A3-73 for Frontotemporal Dementia, and have reported astounding pre-clinical results for epilepsy.....M.J.Fox Foundation is also fully funding a pre-clinical (animal) study of A2-73 for Parkinson's.
Assuming the AAIC results further confirm efficacy of A2-73 in early Alzheimer's, my guess is BTD will likely follow within a few months.
https://www.investorvillage.com/smbd.asp?mb=17701&mn=15583&pt=msg&mid=16128001
See also: Should You Boost Your Choline
http://www.berkeleywellness.com/supplements/vitamins/article/should-you-boost-your-choline
Recent AVXL News
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM